The uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure.

BACKGROUND A relatively high level of serum parathyroid hormone (PTH) is required to maintain normal bone turnover in patients with chronic kidney disease (CKD). 'Uraemic toxins' could cause an impaired response to PTH in bone and result in low turnover bone disease. Since phenylacetic acid (PAA) has been identified as one of the uraemic toxins in patients with CKD and has an inhibiting property of monocyte function, we examined if PAA might inhibit osteoblastic functions in vitro. METHODS Using mouse osteoblastic MC3T3-E1 cells, we performed BrdU incorporation, real-time PCR, Western blot and stainings to see the effect of PAA. RESULTS PAA significantly inhibited proliferation in a dose-dependent manner ranging between 0.5 and 5 mM. PAA reduced osteocalcin mRNA level, alkaline phosphatase activity and osteoblastic mineralization. PAA pre-treatment also decreased both PTH-induced cAMP production and extracellular signal-regulated kinase (ERK) phosphorylation. CONCLUSION PAA, a newly identified uraemic toxin, affects osteoblastic functions such as proliferation, differentiation, mineralization and responsiveness to PTH, indicating that this molecule could play an important role in the pathogenesis of low turnover bone in CKD.

[1]  K. Kurokawa,et al.  Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  S. Ralston,et al.  Regulation of bone mass and bone turnover by neuronal nitric oxide synthase. , 2004, Endocrinology.

[3]  M. Petersson,et al.  Inhibited anabolic effect of insulin-like growth factor-I on stromal bone marrow cells in endothelial nitric oxide synthase-knockout mice. , 2004, Acta physiologica Scandinavica.

[4]  H. Hassan,et al.  Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 106-01 osteoblast-like cells. , 2004, Kidney international.

[5]  J. Jankowski,et al.  Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. , 2003, The Journal of clinical investigation.

[6]  Raymond Vanholder,et al.  Review on uremic toxins: classification, concentration, and interindividual variability. , 2003, Kidney international.

[7]  R. Kitazawa,et al.  Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. , 2003, European journal of endocrinology.

[8]  R. Vanholder,et al.  Effects of uremic ultrafiltrate on the regulation of the parathyroid cell cycle by calcitriol. , 2003, Kidney international.

[9]  K. Martin,et al.  Metabolic acidosis up-regulates PTH/PTHrP receptors in UMR 106-01 osteoblast-like cells. , 2002, Kidney international.

[10]  K. Chihara,et al.  Smad3 Promotes Alkaline Phosphatase Activity and Mineralization of Osteoblastic MC3T3‐E1 Cells , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  A. Freemont,et al.  Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. , 2000, Kidney international.

[12]  S. Mohan,et al.  Evaluation of IGF System Component Levels and Mitogenic Activity of Uremic Serum on Normal Human Osteoblasts , 2000, Nephron.

[13]  J M Polak,et al.  Mechanical Strain Stimulates Nitric Oxide Production by Rapid Activation of Endothelial Nitric Oxide Synthase in Osteocytes , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  M. Inaba,et al.  Lymphoblastoid interferon-alpha downregulates parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor expression in human osteoblastic cells (Saos-2). , 1998, Bone.

[15]  S. Ralston,et al.  Estrogen upregulates endothelial constitutive nitric oxide synthase expression in human osteoblast-like cells. , 1998, Endocrinology.

[16]  K. Martin,et al.  Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR 106-01 osteoblast-like cells. , 1996, Kidney international.

[17]  H. Jüppner,et al.  Down-regulation of the receptor for parathyroid hormone (PTH) and PTH-related peptide by transforming growth factor-beta in primary fetal rat osteoblasts. , 1995, Endocrinology.

[18]  R. Vanholder,et al.  Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. , 1995, The Journal of clinical investigation.

[19]  P. W. Johnston,et al.  Nitric oxide: A cytokine‐induced regulator of bone resorption , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  B. Lacour,et al.  Parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats. , 1995, Kidney international.

[21]  D Hernández,et al.  Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. , 1995, Kidney international.

[22]  H. Jüppner,et al.  Rapid desensitization of parathyroid hormone dependent adenylate cyclase in perifused human osteosarcoma cells (SaOS-2). , 1994, Biochimica et biophysica acta.

[23]  P. Nibbering,et al.  Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. , 1994, The Journal of clinical investigation.

[24]  K. Chihara,et al.  Cross‐talk of parathyroid hormone‐responsive dual signal transduction systems in osteoblastic osteosarcoma cells: Its role in PTH‐induced homologous desensitization of intracellular calcium response , 1994, Journal of cellular physiology.

[25]  R. Vanholder,et al.  Mechanism of decreased intestinal calcitriol receptor concentration in renal failure. , 1993, The American journal of physiology.

[26]  Y. Pei,et al.  The spectrum of bone disease in end-stage renal failure--an evolving disorder. , 1993, Kidney international.

[27]  M. Monier‐Faugere,et al.  Risk of adynamic bone disease in dialyzed patients. , 1992, Kidney international. Supplement.

[28]  G. Mundy,et al.  Tumor necrosis factor and interleukin 1 inhibit parathyroid hormone‐responsive adenylate cyclase in clonal osteoblast‐like cell by down‐regulating parathyroid hormone receptors , 1992 .

[29]  L. Quarles,et al.  Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. , 1992, The Journal of clinical endocrinology and metabolism.

[30]  T. Martin,et al.  A potent inhibitor of osteoclastic bone resorption within a highly conserved pentapeptide region of parathyroid hormone-related protein; PTHrP[107-111]. , 1991, Endocrinology.

[31]  M. Fukase,et al.  Protein kinase C is involved in PTH-induced homologous desensitization by directly affecting PTH receptor in the osteoblastic osteosarcoma cells. , 1991, Endocrinology.

[32]  G. Howard,et al.  Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma. , 1991, Kidney international.

[33]  R. Nissenson,et al.  Desensitization of parathyroid hormone receptors on cultured bone cells , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  R. Jilka,et al.  Homologous and Heterologous Control of Bone Cell Adenosine 3′,5′-Monophosphate Response to Hormones by Parathormone, Prostaglandin E2, Calcitonin, and 1,25-hydroxycholecalciferol* , 1980 .

[35]  S. Massry,et al.  Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. , 1973, Annals of internal medicine.

[36]  R. Dziak,et al.  Effects of tumor necrosis factor alpha on parathyroid hormone-induced increases in osteoblastic cell cyclic AMP , 2007, Calcified Tissue International.

[37]  J. Polak,et al.  Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. , 2001, The American journal of pathology.

[38]  D. Reid,et al.  Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. , 2001 .

[39]  L. Kedes,et al.  PTH-PTHrP receptor mRNA is downregulated in chronic renal failure. , 1994, American journal of nephrology.

[40]  B. Descamps-Latscha,et al.  Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. , 1990, Kidney international.